PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...

The presented posters “ Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations ” and “ ...

A poster of Hezbollah leader Sayyed Hassan Nasrallah is placed ... It was unclear how far the alleged plot had advanced. The ...

Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 ...

Alkermes plc today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 20, 2024. Now in its seventh year, this competitive ...

Event at Bustleton Library Bustleton Library, 10199 Bustleton Ave., will host a visit by the city Department of Public Health ...

GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody ...

David Pittman (left), who directs the Engineer Research and Development Center (ERDC) for the U.S. Army Corps of Engineers, ...

USF faculty continually demonstrate their skills in conducting high-impact research and innovation to advance frontiers of ...

Sept. 20, 9 a.m.-3 p.m. Sept. 21, Bahia Shrine Center, 3101 E. Semoran Blvd., Apopka, $2, free for ages 11 or younger, ...